180 Wealth Advisors LLC Buys New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

180 Wealth Advisors LLC purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,701 shares of the company’s stock, valued at approximately $210,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after buying an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after buying an additional 46,148 shares during the period. SR One Capital Management LP purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $71,496,000. Charles Schwab Investment Management Inc. grew its position in CRISPR Therapeutics by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after acquiring an additional 15,085 shares during the period. Finally, Norges Bank acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at about $38,661,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Royal Bank of Canada decreased their price objective on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Company dropped their target price on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. JMP Securities reissued a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Finally, Chardan Capital cut their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Stock Up 5.3 %

CRSP stock traded up $2.44 during trading on Thursday, hitting $48.85. The company had a trading volume of 1,390,785 shares, compared to its average volume of 1,588,027. The firm has a 50-day moving average price of $55.91 and a 200-day moving average price of $62.42. The firm has a market cap of $4.15 billion, a PE ratio of -17.76 and a beta of 1.70. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. The company’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.98) EPS. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.52 earnings per share for the current year.

Insider Activity

In other news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.